Evidence map›Paper›PMID 37368355›Full record

ArticleThe oncologist2024

Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy.

Justine Panian, Ava Saidian, Kevin Hakimi, Archana Ajmera, William J Anderson, Pedro Barata, Stephanie Berg, Sabina Signoretti, Steven Lee Chang, Vincent D'Andrea and 18 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 12 institutions in 1 country.

Justine PanianUniversity of California San Diego, Department of Medicine, Division of Hematology-Oncology La Jolla, CA, USA.ORCID 0000-0002-6651-195X
Ava SaidianUniversity of California San Diego, Department of Urology, La Jolla, CA, USA.ORCID 0000-0001-5872-6830
Kevin HakimiUniversity of California San Diego, Department of Urology, La Jolla, CA, USA.ORCID 0000-0002-3067-9128
Archana AjmeraUniversity of California San Diego, Department of Medicine, Division of Hematology-Oncology, La Jolla, CA, USA.
William J AndersonBrigham and Women's Hospital, Department of Pathology, Boston, MA, USA.
Pedro BarataTulane University, Deming Department of Medicine, New Orleans, LA, USA.ORCID 0000-0002-8890-2951
Stephanie BergLoyola University Chicago, Department of Cancer Biology and Internal Medicine, Maywood, IL, USA.
Sabina SignorettiBrigham and Women's Hospital, Department of Pathology, Boston, MA, USA.
Steven Lee ChangBrigham and Women's Hospital, Division of Urology, Boston, MA, USA.
Vincent D'AndreaBrigham and Women's Hospital, Division of Urology, Boston, MA, USA.
Daniel GeorgeDuke Cancer Institute, Department of Medicine, Durham, NC, USA.
Hannah DzimitrowiczDuke Cancer Institute, Department of Medicine, Durham, NC, USA.
Talal El ZarifDana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA.
Hamid EmamekhooUniversity of Wisconsin, Department of Medicine, Madison, WI, USA.
Evan GrossThe University of Washington, Department of Urology, Seattle, WA, USA.
Deepak KilariMedical College of Wisconsin, Department of Internal Medicine, Milwaukee, WI, USA.
Elaine LamUniversity of Colorado Cancer Center, Division of Medical Oncology, Aurora, CO, USA.
Isabel LashgariSan Diego State University, Department of Cell and Molecular Biology, San Diego, CA, USA.
Sarah PsutkaThe University of Washington, Department of Urology, Seattle, WA, USA.
Grant P RauterkusTulane University, Deming Department of Medicine, New Orleans, LA, USA.
Ahmed ShabaikUniversity of California San Diego, Department of Pathology, La Jolla, CA, USA.
Bicky ThapaMedical College of Wisconsin, Department of Internal Medicine, Milwaukee, WI, USA.
Luke WangUniversity of California San Diego, Department of Urology, La Jolla, CA, USA.
Nicole WeiseUniversity of California San Diego, Department of Medicine, Division of Hematology-Oncology La Jolla, CA, USA.
Kendrick YimBrigham and Women's Hospital, Division of Urology, Boston, MA, USA.
Tian ZhangUT Southwestern, Department of Internal Medicine, Dallas, TX, USA.
Ithaar DerweeshUniversity of California San Diego, Department of Urology, La Jolla, CA, USA.
Rana R McKayUniversity of California San Diego, Department of Medicine, Department of Urology, La Jolla, CA, USA.
University of California San Diego · USBrigham and Women's Hospital · USClinical Research Institute · USMedical College of Wisconsin · USTulane University · USUniversity of Washington · USDana-Farber Cancer Institute · USLoyola University Chicago · USSan Diego State University · USSouthwestern Medical Center · USUniversity of Colorado Cancer Center · USUniversity of Wisconsin–Madison · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEven though cytoreductive nephrectomy (CN) was once the standard of care for patients with advanced renal cell carcinoma (RCC), its role in treatment has not been well analyzed or defined in the era of immunotherapy (IO). MATERIALS AND

methodsThis study analyzed pathological outcomes in patients with advanced or metastatic RCC who received IO prior to CN. This was a multi-institutional, retrospective study of patients with advanced or metastatic RCC. Patients were required to receive IO monotherapy or combination therapy prior to radical or partial CN. The primary endpoint assessed surgical pathologic outcomes, including American Joint Committee on Cancer (AJCC) staging and frequency of downstaging, at the time of surgery. Pathologic outcomes were correlated to clinical variables using a Wald-chi squared test from Cox regression in a multi-variable analysis. Secondary outcomes included objective response rate (ORR) defined by response evaluation criteria in solid tumors (RECIST) version 1.1 and progression-free survival (PFS), which were estimated using the Kaplan-Meier method with reported 95% CIs.

resultsFifty-two patients from 9 sites were included. Most patients were male (65%), 81% had clear cell histology, 11% had sarcomatoid differentiation. Overall, 44% of patients experienced pathologic downstaging, and 13% had a complete pathologic response. The ORR immediately prior to nephrectomy was stable disease in 29% of patients, partial response in 63%, progressive disease in 4%, and 4% unknown. Median follow-up for the entire cohort was 25.3 months and median PFS was 3.5 years (95% CI, 2.1-4.9).

conclusionsIO-based interventions prior to CN in patients with advanced or metastatic RCC demonstrates efficacy, with a small fraction of patients showing a complete response. Additional prospective studies are warranted to investigate the role of CN in the modern IO-era.

Indexed as

Carcinoma, Renal CellImmunotherapyKidney NeoplasmsNephrectomyAdultAgedAged, 80 and overCytoreduction Surgical ProceduresFemaleHumansMaleMiddle AgedRetrospective Studiesimmunotherapymetastaticnephrectomypathologicrenal cell carcinoma

Identifiers

PMID37368355
PMCPMC11448883
OpenAlexW4382181350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.